CLINICAL TRIALS PROFILE FOR PHENOXYBENZAMINE HYDROCHLORIDE

All Clinical Trials for PHENOXYBENZAMINE HYDROCHLORIDE

Trial ID	Title	Status	Sponsor	Phase	Start Date	Summary
NCT00620945 ↗	Use of Phenoxybenzamine [PBZ] IV to Assist High Flow Low Pressure Perfusion [HFLPP] on Cardio-pulmonary Bypass	Terminated	The Cleveland Clinic	N/A	2006-06-01	Cardiopulmonary bypass [CPB] in small size bodies can result in decreased peripheral perfusion. This results in anaerobic metabolism as evidenced by lactic acidosis. High flow perfusion results in systemic hypertension which is accentuated by moderate hypothermia commonly used during cardiopulmonary bypass. Phenoxybenzamine [PBZ] is an arteriolar vasodilator that acts by irreversibly blocking the alpha adrenergic receptors. It causes vasodilatation allowing high flow, low pressure CPB. It has been used extensively outside US in Canada, Europe and Australia. In the US oral PBZ is FDA approved, whereas intravenous PBZ is only available as an investigational drug
NCT00590018 ↗	Corticosteroids in Postoperative Critically Ill Neonates With Low Cardiac Output Syndrome With Congenital Heart Disease	Completed	Baylor College of Medicine	Phase 2	2003-02-01	Babies having heart surgery often have problems after surgery with their blood pressure and getting enough blood to their bodies. To treat this they require medicines to keep their blood pressure high enough to get blood to their bodies. The side effects of these medicines include fast heart rates and increasing the amount of work the heart has to do. Corticosteroids are made by the body and help to use the energy in the food people eat, control the chemicals in their blood and maintain their blood pressure. Corticosteroids made by the body may be decreased in patients that have major surgery. Corticosteroids help to increase blood pressure and can decrease the amount of blood pressure medicines a patient requires. Corticosteroids have been shown to increase blood pressure in patients with bacterial infections and in very small, premature babies but have only been studied in a few babies who have had heart surgery. The way corticosteroids work is unknown but may involve decreasing the body's response to being on a heart-lung machine or give steroids not being made by the patient. Corticosteroids have been shown to be helpful in treating many diseases. The purpose of this study is to look at the effects of corticosteroids in babies who have had heart surgery and need blood pressure medicines in the intensive care unit after surgery. Our idea is that getting corticosteroids will allow us to decrease the amount of blood pressure medicines each patient needs and improve how they do after surgery. We also plan to do blood tests to help determine how the corticosteroids are working. It will be randomly determined if the subject receives corticosteroids or salt water. The subject will receive a corticosteroid or salt water once a day for five days. Their vital signs will be monitored, especially blood pressure and their need for medicines to increase their blood pressure. Blood work will also be obtained to determine their body's ability to make steroids.
NCT00569855 ↗	Intravenous Phenoxybenzamine Use in Pediatric Patients Undergoing Open-Heart Surgery	Completed	Arkansas Children's Hospital Research Institute	Phase 2	2001-02-01	Cardiopulmonary bypass is done with a machine that does the work of the heart and lungs during open-heart surgery. This study is to determine if intravenous (i.v.) phenoxybenzamine is safe. This drug lowers the blood pressure, making it easier for the cardiopulmonary bypass machine to deliver blood and oxygen to all of the organs and tissues.
NCT00569855 ↗	Intravenous Phenoxybenzamine Use in Pediatric Patients Undergoing Open-Heart Surgery	Completed	University of Arkansas	Phase 2	2001-02-01	Cardiopulmonary bypass is done with a machine that does the work of the heart and lungs during open-heart surgery. This study is to determine if intravenous (i.v.) phenoxybenzamine is safe. This drug lowers the blood pressure, making it easier for the cardiopulmonary bypass machine to deliver blood and oxygen to all of the organs and tissues.

Clinical Trial Conditions for PHENOXYBENZAMINE HYDROCHLORIDE

Condition Name

Condition Name for PHENOXYBENZAMINE HYDROCHLORIDE
Intervention	Trials
Pheochromocytoma	3
Cardiopulmonary Bypass	2
Paraganglioma	2
Adrenergics Causing Adverse Effects in Therapeutic Use	1

Condition MeSH

Condition MeSH for PHENOXYBENZAMINE HYDROCHLORIDE
Intervention	Trials
Pheochromocytoma	3
Paraganglioma	2
Heart Diseases	2
Heart Defects, Congenital	2

Clinical Trial Locations for PHENOXYBENZAMINE HYDROCHLORIDE

Trials by Country

+

−

Trials by Country for PHENOXYBENZAMINE HYDROCHLORIDE
Location	Trials
United States	5
Korea, Republic of	1
Netherlands	1

Trials by US State

+

−

Trials by US State for PHENOXYBENZAMINE HYDROCHLORIDE
Location	Trials
California	1
Tennessee	1
Ohio	1
Texas	1
Arkansas	1

Clinical Trial Progress for PHENOXYBENZAMINE HYDROCHLORIDE

Clinical Trial Phase

Clinical Trial Phase for PHENOXYBENZAMINE HYDROCHLORIDE
Clinical Trial Phase	Trials
Phase 4	2
Phase 3	1
Phase 2	3

Clinical Trial Status

Clinical Trial Status for PHENOXYBENZAMINE HYDROCHLORIDE
Clinical Trial Phase	Trials
Completed	3
Recruiting	2
Terminated	1

Clinical Trial Sponsors for PHENOXYBENZAMINE HYDROCHLORIDE

Sponsor Name

Sponsor Name for PHENOXYBENZAMINE HYDROCHLORIDE
Sponsor	Trials
University of California, Los Angeles	1
Arkansas Children's Hospital Research Institute	1
Leiden University Medical Center	1

Sponsor Type

Sponsor Type for PHENOXYBENZAMINE HYDROCHLORIDE
Sponsor	Trials
Other	23

Phenoxybenzamine Hydrochloride: Clinical Trials, Market Analysis, and Projections

Introduction

Phenoxybenzamine hydrochloride is a potent alpha-adrenergic antagonist used primarily in the management of pheochromocytoma, a rare tumor of the adrenal gland, as well as in treating episodes of hypertension and sweating associated with this condition. Here, we will delve into the current state of clinical trials, market analysis, and future projections for this drug.

Clinical Trials and Usage

Current Clinical Use

Phenoxybenzamine hydrochloride is indicated for the control of episodes of hypertension and sweating in patients with pheochromocytoma. It works by blocking alpha receptors, leading to the relaxation of blood vessel muscles and a subsequent lowering of blood pressure[1][3][4].

Clinical Trials

Several clinical trials and studies have been conducted to evaluate the efficacy and safety of phenoxybenzamine hydrochloride. A systematic review involving 14 studies from 2011 to 2018 showed that phenoxybenzamine was administered intravenously in doses ranging from 10-100 mg/day for durations of 7 days to 10 weeks. These studies highlighted improvements in patient outcomes, particularly in managing blood pressure and reducing cardiovascular complications during surgical resections of pheochromocytoma[3].

Ongoing and Future Trials

While specific ongoing clinical trials for phenoxybenzamine hydrochloride are not detailed in the available sources, the continuous need for effective treatments in rare diseases like pheochromocytoma suggests that research and clinical trials will continue. Future trials may focus on optimizing dosages, exploring combination therapies, and expanding the drug's use to other conditions.

Market Analysis

Market Size and Growth

The phenoxybenzamine hydrochloride market has witnessed significant growth in recent years and is projected to continue this trend. The market is expected to expand substantially from 2023 to 2031, driven by increasing prevalence of hypertension and pheochromocytoma, government initiatives for rare disease research, and collaborative efforts between healthcare providers and pharmaceutical companies[2][5].

Market Segmentation

The market is segmented based on type (99% purity and other), application (tablets, injections), and geographical regions (North America, Europe, Asia-Pacific, South America, and Middle-East and Africa). This segmentation helps in understanding the diverse market dynamics and identifying growth opportunities in different sectors[2][5].

Market Drivers

Key drivers of the phenoxybenzamine hydrochloride market include:

• Growing Prevalence of Conditions: Increasing cases of hypertension and pheochromocytoma necessitate targeted treatments.
• Government Initiatives: Funding for rare disease research and drug affordability programs support market growth.
• Collaborative Efforts: Healthcare providers and pharmaceutical companies work together to enhance patient education and awareness[5].

Market Restraints and Challenges

Despite the positive outlook, the market faces several challenges:

• Economic and Regulatory Challenges: Assessing economic, regulatory, and competitive challenges impacts market penetration.
• Limited Market Penetration: Understanding the reasons behind limited market penetration is crucial for strategic planning.
• Patent Expiration: The impact of patent expiration on exclusivity and market share retention is a significant concern[5].

Market Projections

Future Growth Prospects

The phenoxybenzamine hydrochloride market is poised for significant growth from 2023 to 2031. Projections indicate sustained and substantial expansion, driven by the increasing demand for effective treatments for rare diseases and the ongoing efforts to enhance patient care and education[2][5].

Market Opportunities

Several opportunities exist to further grow the market:

• Data-Driven Marketing: Utilizing data-driven insights to tailor marketing campaigns can increase market penetration.
• Strategic Pricing: Implementing strategic pricing strategies can help expand the market.
• Collaboration with Health Organizations: Collaborating with health organizations to raise awareness about phenoxybenzamine in niche medical fields can also drive growth[5].

Competitive Landscape

The competitive landscape of the phenoxybenzamine hydrochloride market involves a detailed analysis of market share, strategic approaches, product range, certifications, regulatory approvals, and technological developments among leading market players. This analysis is crucial for understanding the market dynamics and identifying potential competitors and partners[5].

Key Takeaways

• Clinical Trials: Phenoxybenzamine hydrochloride has shown efficacy in managing pheochromocytoma and hypertension in clinical trials.
• Market Growth: The market is expected to grow significantly from 2023 to 2031, driven by increasing demand and supportive government initiatives.
• Market Segmentation: The market is segmented by type, application, and geographical regions, each presenting unique growth opportunities.
• Challenges and Opportunities: Despite challenges like patent expiration and limited market penetration, there are opportunities for growth through data-driven marketing and collaboration with health organizations.

FAQs

What is the primary use of phenoxybenzamine hydrochloride?

Phenoxybenzamine hydrochloride is primarily used to treat pheochromocytoma and episodes of hypertension and sweating associated with this condition.

What is the mechanism of action of phenoxybenzamine hydrochloride?

Phenoxybenzamine hydrochloride works by blocking alpha receptors, leading to the relaxation of blood vessel muscles and a subsequent lowering of blood pressure.

What are the key drivers of the phenoxybenzamine hydrochloride market?

Key drivers include the growing prevalence of hypertension and pheochromocytoma, government initiatives for rare disease research, and collaborative efforts between healthcare providers and pharmaceutical companies.

What challenges does the phenoxybenzamine hydrochloride market face?

The market faces challenges such as economic and regulatory hurdles, limited market penetration, and the impact of patent expiration on exclusivity and market share retention.

What are the future growth prospects for the phenoxybenzamine hydrochloride market?

The market is projected to experience significant growth from 2023 to 2031, driven by increasing demand and supportive initiatives.

Sources

1. DrugBank: Phenoxybenzamine: Uses, Interactions, Mechanism of Action.
2. Market Research Intellect: Global Phenoxybenzamine Hydrochloride Market Size, Trends and ...
3. University of Maryland, Baltimore: Phenoxybenzamine hydrochloride.
4. Patsnap: Phenoxybenzamine Hydrochloride - Drug Targets, Indications, Patents.
5. 360 Research Reports: Phenoxybenzamine Hydrochloride Tablets Market Size 2025-2030.